Abstract
Research into new uses for known drugs should be encouraged because the “repurposing” of known drug molecules can be a highly effective route of innovation for pharmaceutical companies. Investment in the development of these products should be rewarded. However, incentives that are designed to reward innovation must be in line with the size and value of the innovation in order to maintain a sustainable balance between incentivizing research and developing and encouraging a competitive market. In the context of encouraging innovation of new uses for known drugs, factors that facilitate access to drug development and innovation should also be considered in addition to incentives.
First Page
253
Recommended Citation
Galit Gonen,
Innovation in Known Drugs—The European Angle,
12 Wash. J. L. Tech. & Arts
253
(2017).
Available at:
https://digitalcommons.law.uw.edu/wjlta/vol12/iss3/5
Included in
Comparative and Foreign Law Commons, Food and Drug Law Commons, Intellectual Property Law Commons